NanoVation Therapeutics
  • Team
  • Technology
  • Partnership
  • News & Events
  • Careers
Select Page
Durable gene expression for treating genetic diseases

Durable gene expression for treating genetic diseases

by NanoVation | Mar 30, 2023 | Liver, Tissue

Adminstration route: i.v. Platform technology: HepLNP Modality: DNA Indication: not disclosed Strategy:...
Durable gene expression for treating genetic diseases

Gene editing in hepatocytes for genetic disease

by NanoVation | Mar 30, 2023 | Liver, Tissue

Adminstration route: i.v. Platform technology: HepLNP Modality: mRNA/gRNA Indication: not disclosed Strategy:...
Durable gene expression for treating genetic diseases

Gene silencing in hepatocytes for genetic disease

by NanoVation | Mar 29, 2023 | Liver, Tissue

Adminstration route: i.v. Platform technology: HepLNP Modality: siRNA Indication: not disclosed Strategy:...

Recent Posts

  • Pieter Cullis & Jay Julkarni @ Next-Generation Nanomedicine symposium
  • Christian Kastrup presents @ MHSRS
  • Pieter Cullis appointed to the Order of British Columbia
  • Christian Kastrup presents guest lecture @ BCCHR
  • Dr. Pieter Cullis elected a Fellow of the Royal Society

Recent Comments

No comments to show.
  • Publications
  • Contact

  • Legal < Privacy Policy

  • Careers
    • Openings
  • News & Events

  • Technology
    • Toolbox
  • Partnership

    • Pipeline
  • Home

  • Team
    • Qualifications
    • Profiles
© NTx 2023